Skip to main content

Articles

Page 7 of 39

  1. Chimeric antigen receptor (CAR)-T cell therapy has demonstrated remarkable success in the treatment of hematologic malignancies, while the success has not yet been replicated in solid tumors. To some extent, t...

    Authors: Zhichen Sun, Rutian Li, Yun Shen, Siyi Tan, Naiqing Ding, Ruihan Xu, Xinyue Wang, Jia Wei, Baorui Liu and Fanyan Meng
    Citation: Journal of Hematology & Oncology 2022 15:29
    Content type: Rapid communication Published on:

  2. Research on tumor immunotherapy has made tremendous progress in the past decades, with numerous studies entering the clinical evaluation. The cancer vaccine is considered a promising therapeutic strategy in th...

    Authors: Jian Liu, Minyang Fu, Manni Wang, Dandan Wan, Yuquan Wei and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2022 15:28
    Content type: Review Published on:

  3. High-grade B-cell lymphoma with translocations involving MYC and BCL2 or BCL6, usually referred to as double hit lymphoma (DHL), is an aggressive hematological malignance with distinct genetic features and poor c...

    Authors: Yuxin Zhuang, Jinxin Che, Meijuan Wu, Yu Guo, Yongjin Xu, Xiaowu Dong and Haiyan Yang
    Citation: Journal of Hematology & Oncology 2022 15:26
    Content type: Review Published on:

  4. Acute myeloid leukemia (AML) patients suffer dismal prognosis upon treatment resistance. To study functional heterogeneity of resistance, we generated serially transplantable patient-derived xenograft (PDX) mo...

    Authors: Christina Zeller, Daniel Richter, Vindi Jurinovic, Ilse A. Valtierra-Gutiérrez, Ashok Kumar Jayavelu, Matthias Mann, Johannes W. Bagnoli, Ines Hellmann, Tobias Herold, Wolfgang Enard, Binje Vick and Irmela Jeremias
    Citation: Journal of Hematology & Oncology 2022 15:25
    Content type: Letter to the Editor Published on:

  5. Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have grea...

    Authors: Mengling Wu, Qianrui Huang, Yao Xie, Xuyi Wu, Hongbo Ma, Yiwen Zhang and Yong Xia
    Citation: Journal of Hematology & Oncology 2022 15:24
    Content type: Review Published on:

  6. KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRASG12C, was recently approved for the treatment of KRASG12C-mutated non-small cell lung cancer (NSCLC). However,...

    Authors: Sajid Khan, Janet Wiegand, Peiyi Zhang, Wanyi Hu, Dinesh Thummuri, Vivekananda Budamagunta, Nan Hua, Lingtao Jin, Carmen J. Allegra, Scott E. Kopetz, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng and Daohong Zhou
    Citation: Journal of Hematology & Oncology 2022 15:23
    Content type: Letter to the Editor Published on:

  7. Steroid-resistant (SR) acute graft-versus-host disease (aGVHD) lacks standard second-line treatment. Mesenchymal stromal cells (MSCs) have potential efficacy in SR aGVHD. We aimed to assess the efficacy and sa...

    Authors: Ke Zhao, Ren Lin, Zhiping Fan, Xiaoyong Chen, Yu Wang, Fen Huang, Na Xu, Xi Zhang, Xin Zhang, Li Xuan, Shunqing Wang, Dongjun Lin, Lan Deng, Danian Nie, Jianyu Weng, Yonghua Li…
    Citation: Journal of Hematology & Oncology 2022 15:22
    Content type: Research Published on:

  8. The circadian rhythm is an evolutionarily conserved time-keeping system that comprises a wide variety of processes including sleep–wake cycles, eating–fasting cycles, and activity–rest cycles, coordinating the...

    Authors: Li Zhou, Zhe Zhang, Edouard Nice, Canhua Huang, Wei Zhang and Yong Tang
    Citation: Journal of Hematology & Oncology 2022 15:21
    Content type: Review Published on:

  9. Sickle cell disease (SCD), which affects approximately 100,000 individuals in the USA and more than 3 million worldwide, is caused by mutations in the βb globin gene that result in sickle hemoglobin production...

    Authors: A. M. Brandow and R. I. Liem
    Citation: Journal of Hematology & Oncology 2022 15:20
    Content type: Review Published on:

  10. The heterogeneity and the complex cellular architecture have a crucial effect on breast cancer progression and response to treatment. However, deciphering the neoplastic subtypes and their spatial organization...

    Authors: Si-Qing Liu, Zhi-Jie Gao, Juan Wu, Hong-Mei Zheng, Bei Li, Si Sun, Xiang-Yu Meng and Qi Wu
    Citation: Journal of Hematology & Oncology 2022 15:19
    Content type: Letter to the Editor Published on:

  11. Non-coding RNAs (ncRNAs) are a large family of RNA molecules with no capability in encoding proteins. However, they participate in developmental and biological processes and their abnormal expression affects c...

    Authors: Sepideh Mirzaei, Mohammad Hossein Gholami, Kiavash Hushmandi, Farid Hashemi, Amirhossein Zabolian, Israel Canadas, Ali Zarrabi, Noushin Nabavi, Amir Reza Aref, Francesco Crea, Yuzhuo Wang, Milad Ashrafizadeh and Alan Prem Kumar
    Citation: Journal of Hematology & Oncology 2022 15:18
    Content type: Review Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:50

  12. Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of malignant plasma cells nurtured within a permissive bone marrow microenvironment. While patients mount numerous adaptive immu...

    Authors: Muthulekha Swamydas, Elena V. Murphy, James J. Ignatz-Hoover, Ehsan Malek and James J. Driscoll
    Citation: Journal of Hematology & Oncology 2022 15:17
    Content type: Review Published on:

  13. The neoadjuvant and adjuvant anti-PD-1/PD-L1 treatment has been increasingly noticed. To summarize the global landscape of these clinical trials will provide essential data for all the stakeholders of drug dev...

    Authors: Dawei Wu, Huiyao Huang, Minghui Zhang, Ziwei Li, Shuhang Wang, Yue Yu, Yuan Fang, Ning Jiang, Huilei Miao, Peiwen Ma, Yu Tang and Ning Li
    Citation: Journal of Hematology & Oncology 2022 15:16
    Content type: Letter to the Editor Published on:

  14. Patients with cancer have an increased risk of coronavirus disease 2019 (COVID-19) and an attenuated responses to various vaccines. This meta-analysis aims to assess the serologic response to COVID-19 vaccinat...

    Authors: Atsushi Sakuraba, Alexander Luna and Dejan Micic
    Citation: Journal of Hematology & Oncology 2022 15:15
    Content type: Research Published on:

  15. Non-coding RNAs (ncRNAs) have been defined as a class of RNA molecules transcribed from the genome but not encoding proteins, such as microRNAs, long non-coding RNAs, Circular RNAs, and Piwi-interacting RNAs. ...

    Authors: Rongyan Zhao, Jiahui Fu, Lingjuan Zhu, Yi Chen and Bo Liu
    Citation: Journal of Hematology & Oncology 2022 15:14
    Content type: Review Published on:

  16. RNA modification plays a crucial role in many biological functions, and its abnormal regulation is associated with the progression of cancer. Among them, N6-methyladenine (m6A) is the most abundant RNA modificati...

    Authors: Qian Guan, Huiran Lin, Lei Miao, Huiqin Guo, Yongping Chen, Zhenjian Zhuo and Jing He
    Citation: Journal of Hematology & Oncology 2022 15:13
    Content type: Review Published on:

  17. Treated secondary acute myeloid leukemia (ts-AML)—i.e., AML arising from a previously treated antecedent hematologic disorder—is associated with very poor outcomes. The optimal frontline treatment regimen for ...

    Authors: Nicholas J. Short, Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron, Courtney D. Dinardo, Naval Daver, Marina Konopleva, Gautam Borthakur, Elizabeth J. Shpall, Uday Popat, Richard E. Champlin, Rohtesh Mehta, Gheath Al-Atrash, Betul Oran…
    Citation: Journal of Hematology & Oncology 2022 15:12
    Content type: Research Published on:

  18. Limited previous studies focused on the death and progression risk stratification of colorectal cancer (CRC) lung metastasis patients. The aim of this study is to construct a nomogram model combing machine lea...

    Authors: Renjie Wang, Weixing Dai, Jing Gong, Mingzhu Huang, Tingdan Hu, Hang Li, Kailin Lin, Cong Tan, Hong Hu, Tong Tong and Guoxiang Cai
    Citation: Journal of Hematology & Oncology 2022 15:11
    Content type: Letter to the Editor Published on:

  19. The members of the Poly(ADP‐ribose) polymerase (PARP) superfamily are involved in several biological processes and, in particular, in the DNA damage response (DDR). The most studied members, PARP1, PARP2 and P...

    Authors: Antonella Padella, Andrea Ghelli Luserna Di Rorà, Giovanni Marconi, Martina Ghetti, Giovanni Martinelli and Giorgia Simonetti
    Citation: Journal of Hematology & Oncology 2022 15:10
    Content type: Review Published on:

  20. Family history of cancer (FHC) is a hallmark of cancer risk and an independent predictor of outcome, albeit with uncertain biologic foundations. We previously showed that FHC-high patients experienced prolonge...

    Authors: Alessio Cortellini, Raffaele Giusti, Marco Filetti, Fabrizio Citarella, Vincenzo Adamo, Daniele Santini, Sebastiano Buti, Olga Nigro, Luca Cantini, Massimo Di Maio, Joachim G. J. V. Aerts, Emilio Bria, Federica Bertolini, Miriam Grazia Ferrara, Michele Ghidini, Francesco Grossi…
    Citation: Journal of Hematology & Oncology 2022 15:9
    Content type: Letter to the Editor Published on:

  21. RNA demethylase ALKBH5 takes part in the modulation of N6-methyladenosine (m6A) modification and controls various cell processes. ALKBH5-mediated m6A demethylation regulates gene expression by affecting multiple ...

    Authors: Jianwei Qu, Haimeng Yan, Yifan Hou, Wen Cao, Yang Liu, Enfan Zhang, Jingsong He and Zhen Cai
    Citation: Journal of Hematology & Oncology 2022 15:8
    Content type: Review Published on:

  23. Anti-CTLA-4 and anti-PD-1/PD-L1 immune checkpoint inhibitors are therapeutic monoclonal antibodies that do not target cancer cells but are designed to reactivate or promote antitumor immunity. Dosing and sched...

    Authors: Christophe Maritaz, Sophie Broutin, Nathalie Chaput, Aurélien Marabelle and Angelo Paci
    Citation: Journal of Hematology & Oncology 2022 15:6
    Content type: Review Published on:

  24. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) through direct lysis of infected lung epithelial cells, which releases damage-associated molecular patter...

    Authors: No-Joon Song, Carter Allen, Anna E. Vilgelm, Brian P. Riesenberg, Kevin P. Weller, Kelsi Reynolds, Karthik B. Chakravarthy, Amrendra Kumar, Aastha Khatiwada, Zequn Sun, Anjun Ma, Yuzhou Chang, Mohamed Yusuf, Anqi Li, Cong Zeng, John P. Evans…
    Citation: Journal of Hematology & Oncology 2022 15:5
    Content type: Research Published on:

  25. There is an urgent need for highly efficacious antiviral therapies in immunosuppressed hosts who develop coronavirus disease (COVID-19), with special concern for those affected by hematological malignancies.

    Authors: P. Guisado-Vasco, M. M. Carralón-González, J. Aguareles-Gorines, E. M. Martí-Ballesteros, M. D. Sánchez-Manzano, D. Carnevali-Ruiz, M. García-Coca, R. Barrena-Puertas, R. García de Viedma, J. M. Luque-Pinilla, G. Sotres-Fernandez, J. M. Fernández-Sousa, X. E. Luepke-Estefan, J. A. López-Martín and J. M. Jimeno
    Citation: Journal of Hematology & Oncology 2022 15:4
    Content type: Letter to the Editor Published on:

  26. Immune suppression is a clinical feature of chronic lymphocytic leukaemia (CLL), and patients show increased vulnerability to SARS-CoV-2 infection and suboptimal antibody responses.

    Authors: Helen Parry, Graham McIlroy, Rachel Bruton, Sarah Damery, Grace Tyson, Nicola Logan, Chris Davis, Brian Willett, Jianmin Zuo, Myah Ali, Manjit Kaur, Christine Stephens, Dawn Brant, Ashley Otter, Tina McSkeane, Hayley Rolfe…
    Citation: Journal of Hematology & Oncology 2022 15:3
    Content type: Research Published on:

  27. Tumor-associated macrophages (TAMs) are major components of the tumor microenvironment (TME) which are closely associated with the tumor malignant progression. However, the regulatory mechanisms by which TAMs ...

    Authors: Hengyu Li, Pinghua Yang, JingHan Wang, Jin Zhang, Qianyun Ma, Yingjie Jiang, Yani Wu, Tao Han and Daimin Xiang
    Citation: Journal of Hematology & Oncology 2022 15:2
    Content type: Letter to the Editor Published on:

  28. The phase 2 PACE (Ponatinib Ph+ ALL and CML Evaluation) trial of ponatinib showed robust long-term benefit in relapsed Philadelphia chromosome-positive (Ph+) leukemia; arterial occlusive events (AOEs) occurred...

    Authors: James L. Januzzi, Joseph M. Garasic, Scott E. Kasner, Vickie McDonald, Mark C. Petrie, Jonathan Seltzer, Michael Mauro, Kevin Croce, Ellin Berman, Michael Deininger, Andreas Hochhaus, Javier Pinilla-Ibarz, Franck Nicolini, Dong-Wook Kim, Daniel J. DeAngelo, Hagop Kantarjian…
    Citation: Journal of Hematology & Oncology 2022 15:1
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:33

  29. The use of immune checkpoint blockade (ICB) using antibodies against programmed death receptor (PD)-1, PD ligand (PD-L)-1, and cytotoxic T-lymphocyte antigen 4 (CTLA-4) has redefined the therapeutic landscape ...

    Authors: Lingling Zhu, Jiewei Liu, Jiang Chen and Qinghua Zhou
    Citation: Journal of Hematology & Oncology 2021 14:206
    Content type: Review Published on:

  30. Understanding the adjacent liver microenvironment of hepatocellular carcinoma (HCC) with possible metastasis tendency might provide a strategy for risk classification of patients and potential therapies by con...

    Authors: Haotian Liao, Jinpeng Du, Haichuan Wang, Tian Lan, Jiajie Peng, Zhenru Wu, Kefei Yuan and Yong Zeng
    Citation: Journal of Hematology & Oncology 2021 14:205
    Content type: Letter to the Editor Published on:

  31. Resistance to anti-cancer monoclonal antibody (mAb) therapy remains a clinical challenge. Previous work in our laboratory has shown that T cell help in the form of interleukin-2 maintains long-term NK cell via...

    Authors: Zhaoming Wang, Chaobo Yin, Lawrence G. Lum, Andrean Simons and George J. Weiner
    Citation: Journal of Hematology & Oncology 2021 14:204
    Content type: Letter to the Editor Published on:

  32. Unbiased genetic forward screening using retroviral insertional mutagenesis in a genetically engineered mouse model of human multiple myeloma may further our understanding of the genetic pathways that govern n...

    Authors: Fumou Sun, Yan Cheng, Jesse D. Riordan, Adam Dupuy, Wendy Dubois, Michael Pisano, Jing Dong, Beverly Mock, Fenghuang Zhan, Parameswaran Hari and Siegfried Janz
    Citation: Journal of Hematology & Oncology 2021 14:203
    Content type: Letter to the Editor Published on:

  33. Soft tissue sarcoma (STS) is a predominantly fatal rare malignancy with inadequate treatment options. Glycogen synthase kinase 3β (GSK-3β) is an emerging target in human malignancies. Its therapeutic relevance...

    Authors: S. Verbeke, R. Perret, V. Chaire, E. Richard, V. Velasco, F. Giles, L. Cavalcante and A. Italiano
    Citation: Journal of Hematology & Oncology 2021 14:202
    Content type: Letter to the Editor Published on:

  34. Amplifications of oncogenic genes are often considered actionable. However, not all patients respond. Questions have therefore arisen regarding the degree to which amplifications, especially non-focal ones, me...

    Authors: Amélie Boichard, Scott M. Lippman and Razelle Kurzrock
    Citation: Journal of Hematology & Oncology 2021 14:201
    Content type: Letter to the Editor Published on:

  35. Immune checkpoint blockade resistance narrows the efficacy of cancer immunotherapies, but the underlying mechanism remains elusive. Delineating the inherent mechanisms of anti-PD1 resistance is important to im...

    Authors: Jia-Cheng Lu, Peng-Fei Zhang, Xiao-Yong Huang, Xiao-Jun Guo, Chao Gao, Hai-Ying Zeng, Yi-Min Zheng, Si-Wei Wang, Jia-Bin Cai, Qi-Man Sun, Ying-Hong Shi, Jian Zhou, Ai-Wu Ke, Guo-Ming Shi and Jia Fan
    Citation: Journal of Hematology & Oncology 2021 14:200
    Content type: Research Published on:

  36. Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be ...

    Authors: Jean Lemoine, Marco Ruella and Roch Houot
    Citation: Journal of Hematology & Oncology 2021 14:199
    Content type: Review Published on:

  37. STAT proteins represent an important family of evolutionarily conserved transcription factors that play key roles in diverse biological processes, notably including blood and immune cell development and functi...

    Authors: Nagendra Awasthi, Clifford Liongue and Alister C. Ward
    Citation: Journal of Hematology & Oncology 2021 14:198
    Content type: Review Published on:

  38. Cancer will soon become the leading cause of death in every country in the twenty-first century. This study aimed to analyze the mortality and morbidity of 29 types of cancer in 204 countries or regions from 1...

    Authors: Longfei Lin, Zhiyong Li, Lei Yan, Yuling Liu, Hongjun Yang and Hui Li
    Citation: Journal of Hematology & Oncology 2021 14:197
    Content type: Research Published on:

  39. Myeloid-derived suppressor cells (MDSCs) are derived from bone marrow progenitor cells commonly, which is a heterogeneous cell group composed of immature granulocytes, dendritic cells, macrophages and early un...

    Authors: Wei Lu, Fenghua Cao, Lili Feng, Ge Song, Yi Chang, Ying Chu, Zhihong Chen, Bo Shen, Huaxi Xu, Shengjun Wang and Jie Ma
    Citation: Journal of Hematology & Oncology 2021 14:196
    Content type: Letter to the Editor Published on:

  40. The multipotent mesenchymal stem/stromal cells (MSCs), initially discovered from bone marrow in 1976, have been identified in nearly all tissues of human body now. The multipotency of MSCs allows them to give ...

    Authors: Tianxia Lan, Min Luo and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2021 14:195
    Content type: Review Published on:

  41. The main cause of death in colorectal cancer patients is metastasis. Accumulating evidences suggest that circRNA plays pivotal roles in cancer initiation and development. However, the underlying molecular mech...

    Authors: Jiehua He, Ziqiang Chu, Wei Lai, Qiusheng Lan, Yujie Zeng, Daning Lu, Shaowen Jin, Heyang Xu, Pengwei Su, Dong Yin, Zhonghua Chu and Lu Liu
    Citation: Journal of Hematology & Oncology 2021 14:194
    Content type: Research Published on:

  42. Acute myeloid leukemia (AML) is a common malignant heterogeneous hematopoietic disease with very low average 5-year survival rate due to the refractory feature and high rate of relapse. CD123 is highly express...

    Authors: Shilin Xu, Meichen Zhang, Xiaocui Fang, Jie Meng, Haiyan Xing, Doudou Yan, Jian Liu, Yanlian Yang, Tao Wen, Weiqi Zhang, Jianxiang Wang, Chen Wang and Haiyan Xu
    Citation: Journal of Hematology & Oncology 2021 14:193
    Content type: Letter to the Editor Published on:

  43. To our knowledge, there is no clinical data pertaining to COVID-19 outcomes and safety of COVID-19 vaccination in Russian patients with genitourinary (GU) malignancies. Aim of our analysis was to describe the ...

    Authors: Ilya Tsimafeyeu, Maria Volkova, Galina Alekseeva, Maria Berkut, Alexander Nosov, Igor Myslevtsev, Andrey Andrianov, Andrey Semenov, Pavel Borisov, Ruslan Zukov, Vadim Goutnik, Sergey Savchuk, Natalia Dengina and Timur Mitin
    Citation: Journal of Hematology & Oncology 2021 14:192
    Content type: Research Published on:

  44. The outcome of patients affected by high-risk or metastatic neuroblastoma (NB) remains grim, with ≥ 50% of the children experiencing relapse or progression of the disease despite multimodal, intensive treatmen...

    Authors: Nicola Tumino, Gerrit Weber, Francesca Besi, Francesca Del Bufalo, Valentina Bertaina, Paola Paci, Linda Quatrini, Laura Antonucci, Matilde Sinibaldi, Concetta Quintarelli, Enrico Maggi, Biagio De Angelis, Franco Locatelli, Lorenzo Moretta, Paola Vacca and Ignazio Caruana
    Citation: Journal of Hematology & Oncology 2021 14:191
    Content type: Letter to the Editor Published on:

  45. Small-cell lung cancer (SCLC) is a devastating subtype of lung cancer with few therapeutic options. Despite the advent of immunotherapy, platinum-based chemotherapy is still the irreplaceable first-line therap...

    Authors: Zhihui Zhang, Chaoqi Zhang, Zhaoyang Yang, Guochao Zhang, Peng Wu, Yuejun Luo, Qingpeng Zeng, Lide Wang, Qi Xue, Yi Zhang, Nan Sun and Jie He
    Citation: Journal of Hematology & Oncology 2021 14:190
    Content type: Letter to the Editor Published on:

  46. The hypoxic microenvironment is presumed to be a sanctuary for myeloid leukemia cells that causes relapse following chemotherapy, but the underlying mechanism remains elusive. Using a zebrafish xenograft model...

    Authors: Yunxin Zeng, Xinyu Zhang, Dongjun Lin, Xiaohui Feng, Yuye Liu, Zhengwen Fang, Weijian Zhang, Yu Chen, Meng Zhao, Jun Wu and Linjia Jiang
    Citation: Journal of Hematology & Oncology 2021 14:189
    Content type: Letter to the Editor Published on:

  47. Accumulating evidence shows that N6-methyladenine (m6A) modulators contribute to the etiology and progression of colorectal cancer (CRC). However, the exact mechanisms of m6A reader involved in glycolytic metabol...

    Authors: Senxu Lu, Li Han, Xiaoyun Hu, Tong Sun, Dongping Xu, Yalun Li, Qiuchen Chen, Weifan Yao, Miao He, Zhenning Wang, Huizhe Wu and Minjie Wei
    Citation: Journal of Hematology & Oncology 2021 14:188
    Content type: Research Published on:

  48. Complex interactions between the immune system and tumor cells exist throughout the initiation and development of cancer. Although the immune system eliminates malignantly transformed cells in the early stage,...

    Authors: Weina Yu, Qingyang Lei, Li Yang, Guohui Qin, Shasha Liu, Dan Wang, Yu Ping and Yi Zhang
    Citation: Journal of Hematology & Oncology 2021 14:187
    Content type: Review Published on:

  49. Poly ADP-ribose polymerase inhibitors (PARPi) have transformed ovarian cancer (OC) treatment, primarily for tumours deficient in homologous recombination repair. Combining VEGF-signalling inhibitors with PARPi...

    Authors: Francesca Bizzaro, Ilaria Fuso Nerini, Molly A. Taylor, Alessia Anastasia, Massimo Russo, Giovanna Damia, Federica Guffanti, Francesca Guana, Paola Ostano, Lucia Minoli, Maureen M. Hattersley, Stephanie Arnold, Antonio Ramos-Montoya, Stuart C. Williamson, Alessandro Galbiati, Jelena Urosevic…
    Citation: Journal of Hematology & Oncology 2021 14:186
    Content type: Letter to the Editor Published on:

  50. Anemia is a common disease which affects around 40% of children and 30% of reproductive age women and can have major health consequences. The present study reports the global, regional and national burden of a...

    Authors: Saeid Safiri, Ali-Asghar Kolahi, Maryam Noori, Seyed Aria Nejadghaderi, Nahid Karamzad, Nicola Luigi Bragazzi, Mark J. M. Sullman, Morteza Abdollahi, Gary S. Collins, Jay S. Kaufman and Jessica A. Grieger
    Citation: Journal of Hematology & Oncology 2021 14:185
    Content type: Research Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us